Sapient provides multiomic biomarker discovery services based on high throughput mass spectrometry, bioinformatics, and access to a longitudinal human biology dataset. Sapient’s insights into dynamic biomarkers enable biopharma to make better decisions when prioritizing targets, patient populations, and drugs during discovery, development, clinical trials, or even following failed trials.
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention, and disease-treatment interventions July 11, 2022—San Diego, CA—Sapient, a biomarker discovery organization focused on rapid, large-scale biomarker profiling, has been awarded a new grant from the Bill & Melinda Gates Foundation to use its rapid liquid chromatography-mass spectrometry (rLC-MS)… Continue reading Sapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry Analysis
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one minute. These technologies are embedded within an integrated discovery pipeline… Continue reading Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to improve drug development and regulatory decision-making. Sapient’s Philip Worboys, PhD, Head of Translational Science,… Continue reading Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium
San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area Lyme Foundation’s 2021 Impact Update report for its collaboration with the Foundation aimed at establishing new diagnostics for persistent Lyme disease (PLD). The report shares insight into the research being conducted by Sapient in leveraging Bay Area… Continue reading Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report
© Care Equity Capital Management L.P. New York, New York
